Emergent BioSolutions

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Emergent BioSolutions addresses revenue challenges, eyes market expansion opportunities

Emergent BioSolutions navigated revenue challenges in Q4 2022, focusing on core businesses and strategic initiatives with a strong financial outlook for 2023.
The company faces competition and market positioning challenges in the OTC space for NARCAN, while opportunities exist in market expansion and government contracts.
Balancing pricing strategies, securing procurement decisions, and extending credit facility maturity are key focus areas for sustained growth and profitability.
Overall, Emergent BioSolutions demonstrates resilience and adaptability in addressing market challenges while capitalizing on opportunities for growth and market expansion.

Emergent BioSolutions (EBS) excels in Q1 with FDA approvals and strategic sales

Emergent BioSolutions (EBS) delivered a robust Q1 performance with notable achievements in FDA approvals and strategic business decisions. While facing challenges in gross margin changes and insurance coverage discussions, EBS remains focused on growth opportunities and product innovation.

Emergent BioSolutions reports Q2 growth, shifts focus to core products

Emergent BioSolutions' Q2 2023 earnings call highlighted positive financial results, strong NARCAN Nasal Spray sales, and strategic shifts towards core products. The company provided updated guidance for 2023, focusing on revenue expectations and cost-saving measures. Analyst questions centered on revenue breakdown, restructuring efforts, and future growth prospects.

Emergent BioSolutions (EBS) exceeds Q3 expectations, focuses on growth

Emergent BioSolutions (EBS) demonstrated strong financial performance in Q3 2023, exceeding revenue and EBITDA expectations. The company's focus on core products, compliance, and cost reduction initiatives positions it well for future growth. Challenges include a rescheduled earnings release and the need to meet growing demand for NARCAN Nasal Spray.

Emergent BioSolutions reports solid Q4 performance and outlines growth strategies

Emergent BioSolutions showcased strong financial performance and operational progress in Q4 2023, setting the stage for a promising 2024.
The company's strategic focus on debt reduction, quality enhancement, and core product strength bodes well for future growth.
While challenges persist in managing product sales variability and addressing stakeholder inquiries, opportunities for expansion and success are abundant.

Emergent BioSolutions excels in Q1, raises 2024 outlook amid growth prospects

Emergent BioSolutions reported strong Q1 performance, raised profit outlook for 2024, and highlighted growth drivers for key products. The company's strategic actions to reduce costs, improve profitability, and focus on core businesses demonstrate a proactive approach to driving long-term value. Despite challenges like potential generic competition, EBS remains well-positioned to leverage growth opportunities and sustain its positive momentum.

Emergent BioSolutions (EBS) exceeds Q2 guidance, poised for growth

Emergent BioSolutions (EBS) delivered strong Q2 results, exceeding revenue guidance and showcasing operational improvements.
The company's strategic actions, product highlights, and financial performance position it well for future growth and value creation.
Challenges in revenue sustainability and operational changes exist, but opportunities in international expansion, partnerships, and innovation are key drivers.
Overall, Emergent's focus on public health preparedness, opioid crisis solutions, and strategic growth initiatives bode well for its long-term success.

Emergent BioSolutions excels in Q3, poised for growth opportunities

Emergent BioSolutions delivered a strong Q3 performance, showcasing financial resilience, operational excellence, and strategic advancements across key business segments.
While facing challenges in pricing dynamics and revenue mix, the company's focus on growth opportunities, compliance, and leadership appointments positions them for sustained success.
With a solid financial foundation, improved guidance, and a strategic roadmap for growth, Emergent is well-equipped to navigate challenges, capitalize on opportunities, and drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Emergent Biosolutions (EBS) came out with a quarterly loss of $3.17 per share versus the Zacks Consensus Estimate of a loss of $1.67. This compares to earnings of $0.18 per share a year ago.

Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue Estimates

Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Emergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy?

GAITHERSBURG, Md., April 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2023, recent business developments, revenue guidance for the second quarter of 2023, and financial outlook for full year 2023.

Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023

Shares of Emergent (EBS) have been rising following the FDA's approval to an OTC version of its Narcan nasal spray.

Emergent Biosciences (EBS) Surges 28% in a Week: Here's Why

Following the FDA approval, Emergent's (EBS) Narcan nasal spray becomes the first OTC product approved for emergency treatment of opioid overdose. This product will be made available by late summer of this year.

Emergent's (EBS) Narcan Gets OTC Status for Opioid Overdose

Philip Morris

Roku

The major indexes are on the rise today, as Wall Street remains optimistic regarding the bank sector's recovery.

3 Stocks Capturing Options Traders' Attention

The FDA approved the use of Narcan as an over-the-counter treatment for opioid overdoses on Wednesday. Narcan has been available as a prescription product in the U.S. since 2016.

Why Emergent BioSolutions Stock Is Soaring Today

Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Emergent Biosolutions (EBS) Surges 5.1%: Is This an Indication of Further Gains?

In a fresh development for the medical and financial communities, the U.S. Food and Drug Administration (FDA) approved Emergent Biosciences' (NASDAQ: EBS ) Narcan nasal spray as an over-the-counter (OTC) emergency opioid overdose treatment. As you might expect, EBS stock traders are responding to this news with high-volume buying activity.

Emergent Biosciences (EBS) Stock Pops as FDA Approves Over-the-Counter Narcan

The nasal spray treats opioid overdoses and will now be available for over-the-counter purchases.

FDA Approves Narcan for Over-the-Counter Use. Emergent Biosolutions Surges.

GAITHERSBURG, Md., March 29, 2023 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved NARCAN ® Naloxone HCl Nasal Spray 4 mg as an over-the-counter (OTC) emergency treatment of opioid overdose. This decision comes at a time when approximately every eight minutes, a person dies from an opioid overdose and research shows the epidemic is escalating in the U.S. with the rise in synthetic opioids. By offering NARCAN® Nasal Spray as an OTC treatment, anyone will be able to access it without a prescription, which is an important step in the fight to reduce the number of opioid overdose deaths occurring each day.

U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions' NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment

The FDA's decision means people will be able to buy the 4mg nasal spray without a prescription in supermarkets, convenience stores and vending machines.

FDA approves over-the-counter sales of lifesaving opioid overdose treatment Narcan nasal spray

J.P. Morgan analyst Jessica Fye downgraded Emergent BioSolutions from neutral to underweight. Fye also slashed the price target for the stock from $23 to $9.

Why Emergent BioSolutions Stock Is Sinking Today

It's not a good day for investors when their company reports a shocking plunge into the red.

Why Emergent BioSolutions Stock Tumbled by Almost 12% Today

Emergent (EBS) reported mixed fourth-quarter 2022 results. While the company significantly misses the mark on earnings, it beat sales estimates.

Emergent's (EBS) Q4 Earnings Miss, Sales Beat Estimates

The consensus price target hints at a 134.3% upside potential for Emergent Biosolutions (EBS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Emergent Biosolutions (EBS) Could Rally 134.29%: Here's is How to Trade

Emergent BioSolutions Inc. (NYSE:EBS ) Q4 2022 Earnings Conference Call February 27, 2023 5:00 PM ET Company Participants Bob Burrows - Vice President, Investor Relations Bob Kramer - President and CEO Rich Lindahl - Chief Financial Officer Conference Call Participants Nick Lenard - JPMorgan Brandon Folkes - Cantor Boris Peaker - Cowen Operator Good day and thank you for standing by. Welcome to the Emergent BioSolutions Fourth Quarter and Full Year 2022 Financial Results Conference Call.

Emergent BioSolutions Inc. (EBS) Q4 2022 Earnings Call Transcript

GAITHERSBURG, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the fourth quarter and year ended December 31, 2022.

Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Emergent Biosolutions (EBS) to Report a Decline in Earnings: What to Look Out for

Emergent BioSolutions has shown a remarkable turnaround since challenging Q3:22 results with a $380 million procurement contract and restructuring plan. Now, a definitive step toward a NARCAN over-the-counter approval.

Emergent BioSolutions: Positive NARCAN FDA Panel, Divesting Travel Health, Raising Rating To Buy

Shares of Emergent BioSolutions Inc. EBS, +12.52% rallied about 19% in premarket trading on Thursday, the day after a Food and Drug Administration advisory committee voted in favor of allowing over-the-counter sales of Narcan, the opioid overdose reversal medication. The FDA is not required to follow the advice of the committee but often does.

Emergent's stock jumps after FDA panel favors over-the-counter sales of Narcan

Emergent Biosolutions (EBS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Emergent Biosolutions (EBS) Moves 12.5% Higher: Will This Strength Last?

GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) --  Today, Emergent BioSolutions Inc. (NYSE:EBS) announced the U.S. Food and Drug Administration (FDA) Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee have unanimously voted in favor (a total of 19 votes) that the benefit-risk profile of NARCAN® (naloxone HCl) Nasal Spray is supportive of its use as a nonprescription opioid overdose reversal agent. Emergent presented an overview of its over-the-counter (OTC) development program, the medical need, Human Factors study data and seven years of post-marketing safety data. The FDA is not bound by the committees' guidance but will take its advice into consideration.

Emergent BioSolutions Reports FDA Advisory Committees' Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use

GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic (BVNRY) for a total value of up to $380 million, including potential future milestone payments. Under the terms of the definitive agreement, Bavarian Nordic will acquire the rights to VIVOTIF®, indicated for the active immunization to prevent typhoid fever, and VAXCHORA®, indicated for the active immunization to prevent cholera, as well as the development-stage chikungunya vaccine candidate CHIKV VLP. Bavarian Nordic will also acquire Emergent's manufacturing site in Bern, Switzerland, and development facilities in San Diego, California. Approximately 280 current Emergent employees are expected to join Bavarian Nordic as part of the transaction.

Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million

COPENHAGEN, Denmark, February 15, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement with Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) to acquire two marketed travel vaccines, Vivotif® for the prevention of typhoid fever and Vaxchora® against cholera as well as a Phase 3 vaccine candidate for the prevention of Chikungunya virus for a total consideration of up to USD 380 million, including USD 270 million in an upfront payment and up to USD 110 million in future conditional milestone payments. The acquisition also includes facilities and key personnel related to the acquired assets.

News for Emergent BioSolutions Stock (EBS)